Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanjivani ParanteralsBOM:531569 -3.24%77 5-Year Yield-on-Cost % is 0.27 as of Sep. 11, 2026, which is at its 10-year median of 0.27. GuruFocus rates BOM:531569 with a GF Score™ of 77/100 and a GF Value™ of ₹243.65 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 506 Drug Manufacturers companies, Sanjivani Paranterals ranks worse than 90.71% on this metric.
Sanjivani Paranterals's yield on cost for the quarter that ended in Jun. 2026 was 0.27.
The historical rank and industry rank for Sanjivani Paranterals's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:531569'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.21 Med: 0.27 Max: 0.37
Current: 0.27
During the past 13 years, Sanjivani Paranterals's highest Yield on Cost was 0.37. The lowest was 0.21. And the median was 0.27.
BOM:531569's 5-Year Yield-on-Cost % is ranked worse than 90.71% of 506
companies
in the Drug Manufacturers industry
Industry Median: 2.39
vs BOM:531569: 0.27
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Sanjivani Paranterals 5-Year Yield-on-Cost % Related Terms
BOM:531569 vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sanjivani Paranterals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanjivani Paranterals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanjivani Paranterals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Sanjivani Paranterals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Sanjivani Paranterals (BOM:531569) has a 5-Year Yield-on-Cost % of 0.27 as of Sep. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sanjivani Paranterals and its competitors. This is near median its historical median of 0.27. Over the past decade, Sanjivani Paranterals' 5-Year Yield-on-Cost % has ranged from 0.21 to 0.37. According to the industry distribution chart, Sanjivani Paranterals ranks #459 out of 506 companies in the Drug Manufacturers industry, placing it in the top 90.7%.
Is Sanjivani Paranterals' 5-Year Yield-on-Cost % too high?
Sanjivani Paranterals' current 5-Year Yield-on-Cost % of 0.27 is near median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 0.37. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.39. Sanjivani Paranterals' value of 0.27 is 88.7% below this industry median. Based on the distribution chart, Sanjivani Paranterals ranks #459 out of 506 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sanjivani Paranterals has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanjivani Paranterals' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sanjivani Paranterals ranks #459 out of 506 companies for 5-Year Yield-on-Cost %. This places Sanjivani Paranterals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.39. Sanjivani Paranterals' value of 0.27 is 88.7% below this benchmark. Historically, Sanjivani Paranterals' own 5-Year Yield-on-Cost % has ranged from 0.21 to 0.37 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 2.39, Sanjivani Paranterals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.39, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanjivani Paranterals's current 5-Year Yield-on-Cost % of 0.27 is 88.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Sanjivani Paranterals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanjivani Paranterals's current 5-Year Yield-on-Cost % is 0.27, which is near median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanjivani Paranterals stock overvalued right now?
Based on GuruFocus' analysis, Sanjivani Paranterals (BOM:531569) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹243.65, compared to a current price of ₹180.85 — trading 25.8% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.27, which is near median its 10-year median of 0.27 and 88.7% below the Drug Manufacturers industry median of 2.39. Sanjivani Paranterals' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Sanjivani Paranterals (BOM:531569), the current 5-Year Yield-on-Cost % is 0.27 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanjivani Paranterals (BOM:531569) Overvalued in 2026?
Based on GuruFocus' analysis, Sanjivani Paranterals stock appears to be undervalued.
The current stock price of ₹180.85 is trading 25.8% below its estimated GF Value™ of ₹243.65.
GuruFocus considers Sanjivani Paranterals to be Modestly Undervalued.
Key valuation signals for BOM:531569:
5-Year Yield-on-Cost %: 0.27 (near median its 10-year median of 0.27)
GF Value™: ₹243.65 vs. price of ₹180.85 (25.8% below fair value)
Industry Position: 88.7% below the Drug Manufacturers median (#459 of 506)
No single metric tells the full story. See the BOM:531569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanjivani Paranterals Ltd is a pharmaceutical company principally engaged in providing pharmaceutical products and services. The company's main product range includes oral solids and small-volume parenteral and sterile powder formulations. The products offered by the company are anti-biotic, anti-emetic, anti-tuberculosis, anti-diabetic, anti-malarial, anti-fungal, calcium and vitamin, multivitamin, sedative, cardiovascular, anti-gout, and others. The company also provides Liquid Injection, Dry powder Injection, Capsules, Drops, and others. The firm sells its products in India and internationally.
77GF Score
Get the complete analysis for BOM:531569
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531569 has been successfully added to your 
